Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lunai BioworksSTU:2Q5 26 Dividend Yield % is 0.00% as of Jul. 29, 2026. GuruFocus rates STU:2Q5 with a GF Score™ of 26/100. The stock has 6 warning signs investors should review. Among 150 Biotechnology companies, Lunai Bioworks ranks worse than 666666% on this metric.
As of today (2026-07-29), the Trailing Annual Dividend Yield of Lunai Bioworks is 0.00%.
The historical rank and industry rank for Lunai Bioworks's Dividend Yield % or its related term are showing as below:
STU:2Q5's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.33 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Lunai Bioworks's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2Q5 vs BCLI, BIVI, XCUR: Dividend Yield % Comparison
For the Biotechnology subindustry, Lunai Bioworks's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lunai Bioworks Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lunai Bioworks's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Lunai Bioworks's Dividend Yield % falls into.
Lunai Bioworks (STU:2Q5) has a Dividend Yield % of 0.00% as of Jul. 29, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Lunai Bioworks and its competitors. According to the industry distribution chart, Lunai Bioworks ranks #999999 out of 150 companies in the Biotechnology industry.
Is Lunai Bioworks' Dividend Yield % too high?
Lunai Bioworks' current Dividend Yield % is 0.00%. Based on the distribution chart, Lunai Bioworks ranks #999999 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lunai Bioworks has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Lunai Bioworks' Dividend Yield % compare to BCLI and BIVI?
According to the Biotechnology industry distribution chart, Lunai Bioworks ranks #999999 out of 150 companies for Dividend Yield %. This places Lunai Bioworks in the lower half of its industry. The industry median Dividend Yield % is 1.33. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.33, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Lunai Bioworks and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lunai Bioworks's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lunai Bioworks stock overvalued right now?
Lunai Bioworks (STU:2Q5) has a current Dividend Yield % of 0.00%. The current Dividend Yield % is 0.00%. Lunai Bioworks' overall GF Score™ is 26/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Lunai Bioworks (STU:2Q5), the current Dividend Yield % is 0.00% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
26GF Score
Get the complete analysis for STU:2Q5
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2Q5 has been successfully added to your 
